How does VLS's PE Ratio compare to its peers?

VLS is good value based on its Price-To-Earnings Ratio (12.3x) compared to the peer average (14.8x).

How does VLS's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

VLS is good value based on its Price-To-Earnings Ratio (12.3x) compared to the Global Pharmaceuticals industry average (22.8x).

What is VLS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate VLS's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of VLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

VLS (A$2.06) is trading below our estimate of [[fair value]] (A$11.81)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Vita Life Sciences (ASX:VLS) - Stock Price, News & Analysis

VLS Stock Overview

A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. More details

VLS fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	4/6
Financial Health	6/6
Dividends	4/6

Rewards

Trading at 82.6% below our estimate of its fair value

Earnings have grown 19.8% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (A$118M)

Unstable dividend track record

Shareholders have been diluted in the past year

Vita Life Sciences Limited Competitors

Vitura Health

ASX:VIT

AU$56.4m

ECS Botanics Holdings

ASX:ECS

AU$21.9m

Neuren Pharmaceuticals

ASX:NEU

AU$1.7b

EZZ Life Science Holdings

ASX:EZZ

AU$127.5m

Price History & Performance

Summary of all time highs, changes and price drops for Vita Life Sciences
Historical stock prices
Current Share Price	AU$2.06
52 Week High	AU$2.50
52 Week Low	AU$1.60
Beta	0.49
11 Month Change	-4.63%
3 Month Change	-8.44%
1 Year Change	22.62%
33 Year Change	21.18%
5 Year Change	234.96%
Change since IPO	1,111.76%

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 23

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Aug 28

Recent updates

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 23

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Aug 28

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 28

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Dec 20

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Aug 24

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

May 14

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Mar 18

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Feb 17

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Jan 20

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Dec 22

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Nov 19

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Jul 14

Shareholder Returns

	VLS	AU Pharmaceuticals	AU Market
7D	-0.5%	-11.8%	1.5%
1Y	22.6%	39.8%	17.2%

Return vs Industry: VLS underperformed the Australian Pharmaceuticals industry which returned 39.8% over the past year.

Return vs Market: VLS exceeded the Australian Market which returned 17.2% over the past year.

Price Volatility

Is VLS's price volatile compared to industry and market?
VLS volatility
VLS Average Weekly Movement	5.1%
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: VLS has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: VLS's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1947	n/a	Andrew O'Keefe	vitalifesciences.com

Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company also offers various minerals, herbs, and superfoods. In addition, it provides products for therapeutic areas, such as nervous system; nutritionals; urinary health; weight management; immunity; skin, hair, and nails; liver and digestion; fertility, pregnancy, and postpartum; blood sugar management; cardiovascular health; pain and inflammation; men, women, and children’s health; antioxidants; bones, joints, and muscles; and eye health.

Vita Life Sciences Limited Fundamentals Summary

How do Vita Life Sciences's earnings and revenue compare to its market cap?
VLS fundamental statistics
Market cap	AU$117.69m
Earnings (TTM)	AU$9.39m
Revenue (TTM)	AU$79.17m

12.3x

P/E Ratio

1.5x

P/S Ratio

Is VLS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VLS income statement (TTM)
Revenue	AU$79.17m
Cost of Revenue	AU$32.77m
Gross Profit	AU$46.41m
Other Expenses	AU$37.01m
Earnings	AU$9.39m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.17
Gross Margin	58.61%
Net Profit Margin	11.86%
Debt/Equity Ratio	0%

How did VLS perform over the long term?

See historical performance and comparison

Dividends

4.4%

Current Dividend Yield

55%

Payout Ratio

VLS Stock Overview

Rewards

Risk Analysis

Vita Life Sciences Limited Competitors

ASX:VIT

AU$56.4m

ASX:ECS

AU$21.9m

ASX:NEU

AU$1.7b

ASX:EZZ

AU$127.5m

Price History & Performance

Recent News & Updates

New minor risk - Shareholder dilution

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Upcoming dividend of AU$0.035 per share

First half 2024 earnings released: EPS: AU$0.078 (vs AU$0.074 in 1H 2023)

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

First half dividend increased to AU$0.035

Recent updates

New minor risk - Shareholder dilution

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Upcoming dividend of AU$0.035 per share

First half 2024 earnings released: EPS: AU$0.078 (vs AU$0.074 in 1H 2023)

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

First half dividend increased to AU$0.035

Now 22% undervalued

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Upcoming dividend of AU$0.06 per share

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

New minor risk - Insider selling

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Upcoming dividend of AU$0.03 per share at 3.7% yield

First half 2023 earnings released: EPS: AU$0.074 (vs AU$0.069 in 1H 2022)

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

Investor sentiment improves as stock rises 15%

Upcoming dividend of AU$0.033 per share at 3.9% yield

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Non-Executive Chairman exercised options to buy AU$433k worth of stock.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of AU$0.028 per share

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Independent Non-Executive Director Jonathan Tooth has left the company

Investor sentiment improved over the past week

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Investor sentiment improved over the past week

Upcoming Dividend of AU$0.028 Per Share

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

New 90-day high: AU$1.00